Identification of FDA approved drugs with anti-tumor activity in rhabdomyosarcoma.
|
Massachusetts General Hospital / David Langenau |
Young Investigator Grants |
2009 |
Massachusetts |
Identifying Therapeutic Vulnerabilities in Pediatric AML through Investigation of the MECOM Transcriptional Network |
Boston Children’s Hospital / Richard Voit, MD/PhD |
Young Investigator Grants |
2023 |
Massachusetts |
The Impact of Hypoxia on Epigenetic Changes in Neuroblastoma |
University of Chicago / Sakshi Uppal, PhD |
Young Investigator Grants |
2017 |
Illinois |
Integration of Targeted New Agents with Chemotherapy
|
Children’s Hospital of Philadelphia / Robin Norris, MD |
Young Investigator Grants |
2008 |
Pennsylvania |
Functional Dissection of Oncogenic Enhancers in T-ALL |
Columbia University / Daniel Herranz, PhD |
Young Investigator Grants |
2015 |
New York |
Small-molecule screening for novel pediatric glioma radiosensitizers. |
Yale School of Medicine / Ranjit Bindra |
Young Investigator Grants |
2012 |
Connecticut |
Identification of Novel Treatment Targets by Exploring the Interaction of Rhabdomyosarcoma-Associated Oncogenes with Cellular Context in a Mouse Model of Rhabdomyosarcoma |
Dana-Farber Cancer Institute / Simone Hettmer |
Young Investigator Grants |
2010 |
Massachusetts |
Histone Modification and Hmgn1 Overexpression as Drivers of B-ALL with Polysomy 21 |
Dana-Farber Cancer Institute / Andrew Lane, MD, PhD |
Young Investigator Grants |
2013 |
Massachusetts |
Bcl2-Family Inhibitors in Neuroblastoma: Mechanism of Action, Therapy Resistance, and Development of Biomarkers |
Children’s Hospital of Philadelphia / Claudia Zapata, MD |
Young Investigator Grants |
2019 |
Pennsylvania |
Development of Targeted DNA-damaging Therapy for ATRX-deficient Pediatric Glioblastoma |
University of Michigan / Carl Koschmann, MD |
Young Investigator Grants |
2014 |
Michigan |